BACKGROUND	RTOG 0518 evaluated the potential benefit of zoledronic acid therapy in preventing bone fractures for patients with high grade and/or locally advanced , non-metastatic prostate adenocarcinoma receiving luteinizing hormone-releasing hormone ( LHRH ) agonist and radiotherapy ( RT ) .\